Topic: Drug Pricing

  • Association of Rebates in Part D with Patient OOP and Federal Spending

    Association of Rebates in Part D with Patient OOP and Federal Spending

  • R&D Costs Do Not Explain Elevated U.S. Drug Prices

  • The U.S. Government Should Buy Gilead for $156Bn to Save Money on Hep C

  • Value-Based Pricing for Drugs: Theme and Variations

    Value-Based Pricing for Drugs: Theme and Variations

  • Copay Assistance for Expensive Drugs: A Helping Hand That Raises Costs

  • Overspending Driven by Oversized Single Dose Vials of Cancer Drugs

    Overspending Driven by Oversized Single Dose Vials of Cancer Drugs

  • Pricing in the Market for Anticancer Drugs

  • Do High Drug Prices Drive Innovation, Or Hurt It?

  • Could High Drug Prices Be Bad for Innovation?

  • Unpronounceable Drugs, Incomprehensible Prices